Lourbakos, A.
Yau, N.
de Bruijn, P.
Hiller, M.
Kozaczynska, K.
Jean-Baptiste, R.
Reza, M.
Wolterbeek, R.
Koeks, Z.
Ayoglu, B.
de Klerk, D.
Campion, G.
Zaharieva, I.
Nadarajah, V. D.
Nilsson, P.
Al-Khalili Szigyarto, C.
Muntoni, F.
Lochmüller, H.
Verschuuren, J. J. http://orcid.org/0000-0002-4572-1501
Goemans, N.
Tulinius, M.
Niks, E. H.
de Kimpe, S.
Aartsma-Rus, A.
’t Hoen, Peter A. C. http://orcid.org/0000-0003-4450-3112
Spitali, P. http://orcid.org/0000-0003-2783-688X
Article History
Received: 10 October 2017
Accepted: 4 December 2017
First Online: 20 December 2017
Competing Interests
: LUMC has patents on exon skipping of some of which A.A.R. and P.A.C.t.H. are co-inventors. Upon sublicensing some of these patents to Biomarin, A.A.R. and P.A.C.t.H. have received a share of royalty payments from LUMC. J.J.G.M.V. and E.H.N. report to be involved in clinical trials for Duchenne muscular dystrophy for GSK, Biomarin and Santhera. LUMC receives research funding from the Association française contre les myopathies, the EU, ZonMW, NOW, Prinses Beatrix Spierfonds, PPMD and DPP-NL. A.L., K.K., R.J.B., G.C. and S.d.K. report being employed by Biomarin. F.M. reports having served on scientific advisory boards for Acceleron Pharma, Genzyme, AVI BioPharma, Debiopharma Group, GSK, Biomarin, Servier and Santhera Pharmaceutical. F.M. serves on the editorial board of Neuromuscular Disorders and Neuropediatrics; receives research support from the European Union, the MRC, the Wellcome Trust, the Association Française Contre les Myopathies (AFM), the Muscular Dystrophy Campaign, the GOSH Biomedical Research Centre and the Muscular Dystrophy Association USA, is receiving funding for trials from GSK and the British Heart Foundation and has received funding for trials from AVI BioPharma, Trophos and PTC.